- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Talks About Adding Finenerone as a Recommended Drug in New ADA Guidelines
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), breaks down the reasoning behind the organization's decision to add Bayer's Kerendia (finerenon) as a recommended drug for kidney disease prevention.
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), breaks down the reasoning behind the organization's decision to add Bayer's Kerendia (finerenone) as a recommended drug for kidney disease prevention.
Transcript
What went into the ADA’s decision to add a recommendation for the use of Bayer’s Kerendia (finerenone) for preventing CKD progression and cardiovascular events?
Each year, as we develop the standards of care, we review all of the scientific and medical literature the year before. One of the things that really jumped out was the availability of new treatments to prevent progression of chronic kidney disease and congestive heart failure. Finerenone, a newly approved drug, has had some wonderful evidence and randomized controlled trials to do both of those things. And it was important that we update the standards so that clinicians could understand how they could use this new treatment modality.
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care
October 17th 2024Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
